All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Update on triplet therapy with ivosidenib, venetoclax, and azacitidine
Bookmark this article
During the 2022 ASCO Annual Meeting, the AML Hub spoke with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked for an update on triplet therapy with ivosidenib, venetoclax, and azacitidine.
Update on triplet therapy with ivosidenib, venetoclax, and azacitidine.
In this video, Lachowiez discusses an updated analysis of the completed phase Ib portion of the study of ivosidenib combined with venetoclax, either with/without azacitidine, presented at ASCO 2022. Lachowiez outlines the study design and enrollment criteria, then goes on to discuss adverse effects and response rates for the different patient groups. Finally, Lachowiez describes findings on IDH-1 clearance rates, overall survival, MRD, and the upcoming phase II expansion cohorts.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox